Galectin Therapeutics (GALT) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.46% |
| Dec 31, 2025 | -50.39% |
| Sep 30, 2025 | -44.05% |
| Jun 30, 2025 | -39.95% |
| Mar 31, 2025 | -36.73% |
| Dec 31, 2024 | -34.42% |
| Sep 30, 2024 | -31.77% |
| Jun 30, 2024 | -29.77% |
| Mar 31, 2024 | -60.55% |
| Dec 31, 2023 | -69.46% |
| Sep 30, 2023 | -56.07% |
| Jun 30, 2023 | -53.65% |
| Mar 31, 2023 | -118.64% |
| Dec 31, 2022 | -129.74% |
| Sep 30, 2022 | -93.89% |
| Jun 30, 2022 | -43.75% |
| Mar 31, 2022 | -24.58% |
| Dec 31, 2021 | -38.67% |
| Sep 30, 2021 | -6.09% |
| Jun 30, 2021 | 15.51% |
| Mar 31, 2021 | 5.77% |
| Dec 31, 2020 | 4.49% |
| Sep 30, 2020 | 18.36% |
| Jun 30, 2020 | 14.57% |
| Mar 31, 2020 | 13.43% |
| Dec 31, 2019 | 15.66% |
| Sep 30, 2019 | 15.52% |
| Jun 30, 2019 | 14.17% |
| Mar 31, 2019 | -28.95% |
| Dec 31, 2018 | 28.43% |
| Sep 30, 2018 | 41.00% |
| Jun 30, 2018 | 35.73% |
| Mar 31, 2018 | 23.67% |
| Dec 31, 2017 | -19.68% |
| Sep 30, 2017 | -20.89% |
| Jun 30, 2017 | -3.55% |
| Mar 31, 2017 | 3.00% |
| Dec 31, 2016 | 46.91% |
| Sep 30, 2016 | 65.78% |
| Jun 30, 2016 | 52.26% |
| Dec 31, 2015 | 66.12% |